Zack Pemberton-Whiteley – CEO, Leukaemia Care

Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA, and his take on moving CAR-T cells to an earlier line of therapy.  
We are calling strongly for a greater role in ensuring that the right treatments are approved, the ones that matter most to patients. The only way you can do that is by listening to patients with the specific experience of the particular indication and looking at what matters to them
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report